2. Protein Tyrosine Kinase/RTK Apoptosis
  3. VEGFR Apoptosis
  4. Anti-Mouse VEGFR-2 Antibody (DC101)

Anti-Mouse VEGFR-2 Antibody (DC101) 

Cat. No.: HY-P990106 Purity: 99.41%
COA
SDS
Technical Support

Anti-Mouse VEGFR-2 Antibody (DC101) is a rat anti-mouse VEGFR2 monoclonal antibody. Anti-Mouse VEGFR-2 Antibody (DC101) inhibits tumor angiogenesis by blocking the binding of VEGF and VEGFR2. Anti-Mouse VEGFR-2 Antibody (DC101) promotes immune cell infiltration and induces tumor cell apoptosis. Anti-Mouse VEGFR-2 Antibody (DC101) can be used for research on various types of cancer such as melanoma, lung cancer and breast cancer .

For research use only. We do not sell to patients.

Size Price Stock Quantity
1 mg In-stock
5 mg In-stock
10 mg In-stock
50 mg   Get quote  
100 mg   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 1 publication(s) in Google Scholar

Anti-Mouse VEGFR-2 Antibody (DC101) Featured Recommendations:

Anti-Mouse VEGFR-2 Antibody (DC101) Related Antibodies

Top Publications Citing Use of Products

View All VEGFR Isoform Specific Products:

View All Isoforms
VEGFR1/Flt-1 VEGFR2/KDR/Flk-1 VEGFR3/Flt-4

  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

Anti-Mouse VEGFR-2 Antibody (DC101) is a rat anti-mouse VEGFR2 monoclonal antibody. Anti-Mouse VEGFR-2 Antibody (DC101) inhibits tumor angiogenesis by blocking the binding of VEGF and VEGFR2. Anti-Mouse VEGFR-2 Antibody (DC101) promotes immune cell infiltration and induces tumor cell apoptosis. Anti-Mouse VEGFR-2 Antibody (DC101) can be used for research on various types of cancer such as melanoma, lung cancer and breast cancer [1][2][3][4][5][6].

Isotype

Rat IgG1 kappa
Recommend Isotype Controls
IC50 & Target[1][2][3][4][5][6]

VEGFR2

 

In Vivo

Anti-Mouse VEGFR-2 Antibody (DC101) (1 mg/dose, i.p., twice weekly, for 4 weeks) significantly induces apoptosis of tumor cells and endothelial cells, and significantly inhibits angiogenesis in male athymic BALB/c nude mice bearing 253J B-V tumors[1].
Anti-Mouse VEGFR-2 Antibody (DC101) (10 mg/kg, i.p., on day 2, 5 and 8) significantly inhibits tumor growth without significant toxicity in female BALB/c mice bearing H22 tumors[2].
Anti-Mouse VEGFR-2 Antibody (DC101) (40 mg/kg, i.g., once every three days, for 4 weeks) significantly inhibits tumor growth and increases immune cell infiltration in female C57BL/6 mice bearing B16-OVA tumors[3].
Anti-Mouse VEGFR-2 Antibody (DC101) (40 mg/kg, i.p., three times every week, for 21 days) significantly inhibits wound induced tumors in transgenic mice expressing CER of HPV8[4].
Anti-Mouse VEGFR-2 Antibody (DC101) (0.8 mg/mouse, i.p., twice weekly, for 2-3 weeks) inhibits tumor growth and increases T cell infiltration in FVB mice and Neu-N mice bearing NT2.5 tumors[5].
Anti-Mouse VEGFR-2 Antibody (DC101) (100 or 400 μg, i.p., once every three days, for 21 days) significantly reduces angiogenesis and endothelial cell count in female C57BL/6 mice injected with bFGF and VEGF[6].
Anti-Mouse VEGFR-2 Antibody (DC101) (800 μg, i.p., once every three days) significantly inhibits the growth of various tumors[6].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: 1×106 253J B-V cells injected male athymic BALB/c nude mice (8-12 weeks)[1]
Dosage: 1 mg/dose, combined with Paclitaxel (HY-B0015) 10 mg/kg
Administration: Intraperitoneal injection (i.p.), twice weekly for 4 weeks
Result: Significantly prolonged the survival period of mice.
Significantly reduced tumor microvascular density.
Enhanced apoptosis of tumor cells and endothelial cells.
Animal Model: 2×106 H22 cells injected female BALB/c mice (6-8 weeks, 20 g)[2]
Dosage: 10 mg/kg, combined with CA4 NPs (45 mg/kg) and anti-PD-1 (100 μg/mouse)
Administration: Intraperitoneal injection (i.p.) on day 2, 5 and 8
Result: Increased the number of CD8+ T cells within the tumor.
Significantly improved vascular perfusion.
Reduced the level of IFN-γ and TNF-α.
Had good safety in vivo.
Animal Model: 5×105 B16-OVA cells injected female C57BL/6 mice (6-8 weeks)[3]
Dosage: 40 mg/kg
Administration: Oral gavage (i.g.), once every three days for 4 weeks
Result: Significantly inhibited tumor volume.
Increased infiltration of CD3+ and CD8+ T cells.
Increased infiltration of B cells (CD19+) and dendritic cells (CD11c+).
Enhanced the expression of IFN-γ, perforin, and granzyme B in CD8+ T cells.
Reduced vascular density and increased perivascular cell coverage.
Significantly increased the density of PNAd+HEV and promoted the formation of tertiary lymphoid structures (TLS).
Upregulated PD-L1 expression in tumor cells and CD45+ immune cells, as well as PD-1 expression in CD3+ T cells.
Animal Model: Transgenic mice expressing CER of HPV8[4]
Dosage: 40 mg/kg
Administration: Intraperitoneal injection (i.p.), three times every week for 21 days
Result: Reduce Ki-67+ proliferating cells and CD31+ vascular density.
Animal Model: 5×106 NT2.5 cells injected FVB mice and Neu-N mice[5]
Dosage: 0.8 mg/mouse
Administration: Intraperitoneal injection (i.p.), twice weekly for 2-3 weeks
Result: Increased CD4+ and CD8+ T cell infiltration.
Significantly inhibited tumor volume.
Decreased angiogenesis and increased tumor cell apoptosis.
Animal Model: Female C57BL/6 injected with bFGF (500 ng) and VEGF (10 μg)[6]
Dosage: 100 or 400 μg
Administration: Intraperitoneal injection (i.p.), once every three days for 21 days
Result: Significantly reduced angiogenesis and endothelial cell count in matrigel plug model.
Animal Model: 2×106 Lewis lung cells or 1×105 B16 cells injected female C57BL/6 mice (5-6 weeks), 1×105 4T1 cells injected female BALB/c mice (5-6 weeks), 2×106 A431, SK-RC-29, BxPC-3 or GBM-18 cells injected female athymic nu/nu mice (5-6 weeks)[6]
Dosage: 800 μg
Administration: Intraperitoneal injection (i.p.), once every three days
Result: Significantly inhibited tumor growth.
Gene ID

16542  [NCBI]

Accession
Application

ELISA, FACS, Functional assay, Research in vivo
Conjugated

Unconjugated
Reconsititution

The product can be reconstituted/diluted with sterile PBS or saline.
Molecular Weight

150 kDa

Appearance

Liquid

Color

Colorless to light yellow

SMILES

[Anti-Mouse VEGFR-2 Antibody (DC101)]
Storage

Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
  • Immobilized VEGFR-2/Flk-1/KDR Fc Chimera Protein, Mouse can bind Anti-Mouse VEGFR-2 Antibody (DC101). The EC50 for this effect is 177.8 ng/mL.
Purity & Documentation

Purity: 99.41%

SDS (251 KB)

COA (232 KB) SDS-PAGE (84 KB) SEC-HPLC (218 KB)

Inhibitory Antibodies User Guide (602 KB)
References
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

Anti-Mouse VEGFR-2 Antibody (DC101) Related Classifications

  • Molarity Calculator

  • Dilution Calculator

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass   Concentration   Volume   Molecular Weight *
= × ×

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
× = ×
C1   V1   C2   V2
Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Anti-Mouse VEGFR-2 Antibody (DC101)VEGFRApoptosisVascular endothelial growth factor receptorVEGFR2apoptosismelanomalung cancerprostate cancerbreast cancerhepatocellular carcinomaInhibitorinhibitorinhibit

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

  

Requested Quantity *

Applicant Name *

 

Salutation

Email Address *

 

Phone Number *

Department

 

Organization Name *

City

State

Country or Region *

      

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
Anti-Mouse VEGFR-2 Antibody (DC101)
Cat. No.:
HY-P990106
Quantity:
MCE Japan Authorized Agent:

Customer Review

Thank You for Your Feedback!

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

Product Name

  

Lot #

Applicant Name *

 

Email Address *

Phone Number

 

Department *

Organization Name *

 

Country or Region *

Remarks

SAFETY DATA SHEET (SDS)

English - EN (251 KB) Français - FR (251 KB) Deutsch - DE (251 KB) Norwegian - NO (251 KB) Español - ES (251 KB) Swedish - SV (251 KB) Italian - IT (251 KB) Portuguese - PT (251 KB)

Request for HNMR Report

We have received your request and will respond to you as soon as possible.